Skip to main content
. 2019 Jun 27;55(2):425–438. doi: 10.3892/ijo.2019.4834

Table III.

Prognostic index for HCC patients based on alternative splicing events.

Symbol AS ID Splice type Coefficient z score P-value
ZFAND6 32171 AA −8.51E-01 −2.83 0.0047
SWI5 87732 AA 8.52E-01 2.46 0.01392
BIRC2 18447 AA −1.28E+01 −4.66 3.20E-06
RPS14 74096 AD −2.55E+00 −4.38 1.20E-05
PGRMC2 70577 AD −3.42E+01 −4.58 4.70E-06
CCDC90B 18085 AD 8.30E-01 2.57 0.0102
APOC1 50361 AD 4.11E+00 3.32 0.00089
RTN4 53584 AP −4.26E-01 −3.29 0.001
RPL23A 39967 AP −9.34E+01 −2.57 0.01003
RPL23A 39965 AP −3.06E+00 −3.44 0.00059
RCL1 85779 AP 4.21E-01 2.92 0.00347
NUDT6 70523 AP 2.19E-01 2.16 0.03054
NUDT6 70521 AP 6.16E-01 3.07 0.00216
MXI1 13080 AP 1.53E-01 1.49 0.13594
MXI1 13079 AP 4.76E-01 2.67 0.00752
IAH1 52628 AP 1.41E+01 4.98 6.30E-07
DUSP22 75126 AP −2.38E-01 −1.76 0.07903
DUSP22 75125 AP 9.50E-01 3.53 0.00041
CYB5A 45803 AP 1.29E+00 3.29 0.00099
CHPF 57718 AP −1.64E+00 −2.21 0.02698
CARKD 26251 AP −2.49E-01 −1.71 0.08786
IAH1 52629 AP 4.82E-01 3 0.00273
ZSCAN20 1679 AT −7.88E-01 −3.12 0.00182
ZNF706 84738 AT −1.42E+01 −5.76 8.40E-09
WWOX 37672 AT −5.47E+00 −7.13 9.70E-13
TROAP 21551 AT 3.63E-01 1.56 0.11927
RAPH1 57075 AT 1.48E+00 1.83 0.0673
RAPH1 57074 AT 5.54E-01 2.8 0.00504
NUCB2 14523 AT −9.05E+00 −2.22 0.0262
FRMD4A 10810 AT 5.09E+00 5.4 6.50E-08
CRISPLD2 37867 AT 8.61E-01 3.72 0.0002
CLSPN 1731 AT −8.03E-01 −1.74 0.08206
BCAM 50347 AT −3.64E-01 −1.6 0.11049
ACAT1 18599 AT 2.88E+00 4.6 4.30E-06
XPC 63523 ES 2.96E-01 1.79 0.0731
WIPI2 78656 ES −3.47E-01 −1.98 0.04758
TRAPPC6A 50409 ES −3.27E+00 −4.69 2.70E-06
TPRA1 66613 ES −4.71E+00 −1.84 0.06575
TMEM150A 54305 ES 1.66E+00 2.85 0.00443
TMEM141 88206 ES −3.62E-01 −3.7 0.00022
TCF3 46542 ES −1.57E+00 −4.66 3.10E-06
STRA13 44266 ES 2.97E+00 4.89 1.00E-06
SSR4 90499 ES 2.39E+02 6.3 3.00E-10
SLC7A9 48907 ES 3.61E-01 3.17 0.0015
SLC25A45 16828 ES 3.71E-01 2.05 0.04004
SLAIN2 69214 ES −6.78E-01 −2.89 0.00385
SHBG 39015 ES −8.49E-01 −7.07 1.50E-12
PTRH1 87649 ES −6.58E+01 −5.47 4.40E-08
PPP2CB 83304 ES −5.52E+02 −5.72 1.10E-08
PGAP3 40670 ES 2.10E+01 3.32 0.00089
OCEL1 48244 ES −5.74E+00 −2.97 0.00298
MTA1 29647 ES −3.93E-01 −2.25 0.02464
MPPE1 44648 ES −3.09E-01 −2.34 0.01921
MPND 46796 ES −6.87E+00 −2.12 0.034
LTBP3 16865 ES −4.93E-01 −1.87 0.06167
JOSD2 51205 ES −5.21E+00 −2.51 0.0119
ISOC2 52106 ES −5.98E+00 −3.29 0.00099
IRF3 50991 ES −7.04E+01 −2.94 0.00327
IRF3 50990 ES 5.08E-01 2.41 0.01599
GUK1 10185 ES −2.01E+01 −3.77 0.00016
ECHDC2 3037 ES 6.27E-01 3.96 7.50E-05
DGKZ 15546 ES −8.54E-01 −2.5 0.01235
CSAD 21952 ES 8.72E-01 3.91 9.30E-05
CLASRP 50393 ES −1.15E+00 −2.99 0.00281
CHRD 67959 ES −5.44E-01 −3.86 0.00011
C17orf49 38825 ES 2.01E+01 3.52 0.00043
C16orf13 32921 ES 2.25E+00 2.39 0.01699
C16orf13 32919 ES −3.45E+00 −3.98 6.80E-05
BAX 50838 ES −4.99E+01 −3.86 0.00011
ARHGEF10L 862 ES 4.31E-01 1.83 0.06684
APOC1 99361 ES −2.72E-01 −3.56 0.00037
AFMID 94694 ES 2.79E-01 1.98 0.04811
AFMID 94690 ES 4.05E-01 2.62 0.00888
AFMID 43800 ES −1.21E+00 −4.21 2.50E-05
AFMID 43798 ES 7.48E-01 3.04 0.00236
AFMID 43795 ES −5.04E-01 −4.01 6.00E-05
ACY1 65150 ES 3.56E+01 1.76 0.07779
SLC39A14 140283 ME 3.82E-01 2.9 0.00372
H2AFY 96931 ME 2.26E+00 3.09 0.00198
CYP4F3 48101 ME −3.19E-01 −2.94 0.00327
VPS28 85600 RI −7.11E-01 −2.25 0.02443
ROMO1 59223 RI 7.85E-01 2.64 0.00822
NUDT22 16590 RI 2.71E+00 5.83 5.70E-09
MRPL52 26642 RI 1.11E+00 4.03 5.60E-05

AS, alternative splicing; HCC, hepatocellular carcinoma; AA, alternate acceptor sites; AD, alternate donor sites; AP, alternate promoters; AT, alternate terminators; ES, exon skipping; ME, mutually exclusive exons; RI, retained introns.